Cargando…

Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor

Weight gain is a known adverse effect of ruxolitinib, a JAK1/2 inhibitor that is the mainstay of treatment for many patients with myelofibrosis. The mechanisms behind weight increase with ruxolitinib is incompletely understood, although decreased adipose tissue lipolysis and increased appetite due t...

Descripción completa

Detalles Bibliográficos
Autores principales: Tremblay, Douglas, Dougherty, Mikaela, Mascarenhas, John, Gallagher, Emily Jane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339379/
https://www.ncbi.nlm.nih.gov/pubmed/37455900
http://dx.doi.org/10.3389/fendo.2023.1141029
_version_ 1785071831505436672
author Tremblay, Douglas
Dougherty, Mikaela
Mascarenhas, John
Gallagher, Emily Jane
author_facet Tremblay, Douglas
Dougherty, Mikaela
Mascarenhas, John
Gallagher, Emily Jane
author_sort Tremblay, Douglas
collection PubMed
description Weight gain is a known adverse effect of ruxolitinib, a JAK1/2 inhibitor that is the mainstay of treatment for many patients with myelofibrosis. The mechanisms behind weight increase with ruxolitinib is incompletely understood, although decreased adipose tissue lipolysis and increased appetite due to blocking the effects of leptin in the hypothalamus have been proposed. In order to explore the metabolic changes in ruxolitinib-treated patients with myelofibrosis, we performed a pilot study to assess the feasibility of using a portable indirect calorimeter to quantify energy expenditure before and during ruxolitinib treatment and report the results of two patients. Waist circumference increased during ruxolitinib treatment in both patients. Energy expenditure initially increased followed by a decrease and then increase again, but to levels below baseline. These results suggest that weight gain secondary to ruxolitinib may be related to changes in whole body energy expenditure.
format Online
Article
Text
id pubmed-10339379
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103393792023-07-14 Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor Tremblay, Douglas Dougherty, Mikaela Mascarenhas, John Gallagher, Emily Jane Front Endocrinol (Lausanne) Endocrinology Weight gain is a known adverse effect of ruxolitinib, a JAK1/2 inhibitor that is the mainstay of treatment for many patients with myelofibrosis. The mechanisms behind weight increase with ruxolitinib is incompletely understood, although decreased adipose tissue lipolysis and increased appetite due to blocking the effects of leptin in the hypothalamus have been proposed. In order to explore the metabolic changes in ruxolitinib-treated patients with myelofibrosis, we performed a pilot study to assess the feasibility of using a portable indirect calorimeter to quantify energy expenditure before and during ruxolitinib treatment and report the results of two patients. Waist circumference increased during ruxolitinib treatment in both patients. Energy expenditure initially increased followed by a decrease and then increase again, but to levels below baseline. These results suggest that weight gain secondary to ruxolitinib may be related to changes in whole body energy expenditure. Frontiers Media S.A. 2023-06-29 /pmc/articles/PMC10339379/ /pubmed/37455900 http://dx.doi.org/10.3389/fendo.2023.1141029 Text en Copyright © 2023 Tremblay, Dougherty, Mascarenhas and Gallagher https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Tremblay, Douglas
Dougherty, Mikaela
Mascarenhas, John
Gallagher, Emily Jane
Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor
title Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor
title_full Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor
title_fullStr Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor
title_full_unstemmed Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor
title_short Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor
title_sort energy expenditure in myelofibrosis patients treated with a jak1/2 inhibitor
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339379/
https://www.ncbi.nlm.nih.gov/pubmed/37455900
http://dx.doi.org/10.3389/fendo.2023.1141029
work_keys_str_mv AT tremblaydouglas energyexpenditureinmyelofibrosispatientstreatedwithajak12inhibitor
AT doughertymikaela energyexpenditureinmyelofibrosispatientstreatedwithajak12inhibitor
AT mascarenhasjohn energyexpenditureinmyelofibrosispatientstreatedwithajak12inhibitor
AT gallagheremilyjane energyexpenditureinmyelofibrosispatientstreatedwithajak12inhibitor